

Challenges to Establish a HCV Therapy access program in Brazil and Latin America




R. PARANÁ
Federal University of Bahia, Brazil
HUPES-University Hospital
Gastro-Hepatology Unit



Burden of HCV infection

Brazil: more than 2 million people with chronic HCV infection

- Less than 15% diagnosed
- Less than 10% treated
- Less than 5% cured




LATIN AMERICA

07-15 Million
> 20% cases

Are In Brazil

Gen 1a ~ 35%
1b ~35%
3 ~25%
2 ~5%



Hepatitis C In Brazil

→ 50% of Liver transplantation indications
50 - 75% of HCC etiology in some referral centers

-- → 45 yo = 3 %

(Brazilian Hepatology Society recommendations for screening)

Estimation of 1,2 - 2 million HCV carriers

Homogeneous distribution, mainly in urban areas

Hotly debated topic
How could we change this scenario?

Health system in Brazil and LATAM

- Brazilian constitution guarantees access to public Health system, including treatment with high cost medications
 - Health Minister Has a department for HIV and Viral Hepatitis
- Treatment is NOT based on GUIDELINES , but on PUBLIC HEALTH POLICIES:**

Scientific Evidence x Budget x Logistic aspects

In most LATAM countries, there is no treatment access in the Public Health System

-Chile, Argentina covered by private insurance

- Mexico has a mixed system: private insurance/public

-In Peru , theoretically, public health system, but the acces is restricted

Little information from Caraibean and other SA countries

New Brazilian Health Ministry Protocol

Priorities: F3/4 (by LB or FIB4 or APRI or Fibroscan or clinical findings)

Drug Registration Status: DCV registered / SOF and SMP under registration process)

Estimated availability: as of May 2015

Estimated number of pts treated /year: 20,000 in referral and non-referral centers

–Gen 1 F3/4: SOF + SMV or SOF + DCV (PI exposed pts)

–Gen 3 – If INF Tolerated SOF + PR INF-free regimens: SOF + DCV with or without Riba

– Gen 2 : PR or SOF + Riba, depending on INF tolerance and previous treatment PR + SOF in cirrhotic experienced pts

Treatment of HCV patients who are on liver transplantation list

CP A : P/R + SOF or SOF + RIBA or SOF + DCV (SOF + SMP in Gen 1 pts not exposed to PIs)

CP B: SOF + RIBA or SOF + DCV

Treatment of HCV patients post-liver transplantation

Gen 1: SOF + SMV (no PIs exposure) or SOF + DCV

Gen 2: SOF + RIBA

Gen 3: SOF + DCV



Le Brésil est Charlie

Merci
Thank you

www.hepatologiadomilenio.com.br